UBS

Only 5 percent of respondents said they got tested through a consumer genomics firm, but the future market could be worth as much as $7 billion, analysts at UBS estimated.

A Cepheid executive today provided investors with an update on the company's molecular diagnostic pipeline, stating that the firm currently has 14 tests in development for its automated GeneXpert platform and that it expects to offer the broadest test menu of any molecular diagno

Several mass spec vendors presented this week at the UBS Global Life Sciences Conference in New York City, offering information on various aspects of their businesses, including portions of their proteomics portfolios.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – The UBS Global Life Sciences Conference concluded on Wednesday with presentations in the afternoon by GenturaDx and Epigenomics.

Speaking at the UBS Global Life Sciences conference in New York on Monday, Bio-Rad Laboratories President and CEO Norman Schwartz told attendees that Bio-Rad planned to launch the platform to test for sexually transmitted diseases.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.